XXXX call. with for of you meaningful for believe our immune are and to that and I'm our first would excited and tool Alex, we January, we approach focus using clinical everyone, as clinical our When clinical programs advancement first on guided you that, additional you, to X X we data in today Affimed assets of our thank fight of Thank our data share the all generate on all strategic for of year. programs joining an the Yes. validating reorganization the day, the in cancer. innate as to us the goal system today of announced earnings half our be quarter good
I'm to proud to say all of and can to on that coworkers this Affimed clinical and guidance. today, all my investigators thankful deliver at our we
As Slide all validation shown we X now have assets. X, on clinical for
For that EGFR AFMXX, durable for EGFR both in we lung or wild-type ongoing we are with with Data patients X cancer, treatment-refractory X over the advancing non-small with X mutant responses at atezolizumab in subgroups. shared ASCO with tumors the now EGFR in and combination cell the in demonstrate study patients months. wild-type responses
meaningful is unresponsive and the immunotherapy. EGFR considered confirmed responses mutant tumor type generally see also subgroup, in We that tumor the to
of the our data REIT PT can independent assessed in We cells Hodgkin's primary trial LuminICE AlloNK study their clinical -- with meanwhile ] had be of lymphoma. share FDA. endpoint exciting patients the agreed by refractory will with patients also have [ combination Several scans, which blinded symptomic for CT upon scans as in with
see In objective for responses of rate these X out we overall an patients, of response X patients XX.X%. in
with X includes this a remission. patients complete Importantly,
have AML our with X single-agent Finally, the of has ICE in escalation response patients X AFMXX, of activity. X dose disease. level for treatment observed A our CDXXX refractory stable we remarkable targeting dose complete shown clinical study,
with stable with dose and disease. X see At patients CRI, level response X we complete the patients in X respectively, a
are further at level development. dose X a further responses. dose X now establishing from and response on ongoing safe more for observed were and complete level regimen treatment toxicities dose X X in the is importantly, continuing for X the of than possibility And Also X stable X, of patients for Importantly, their dose-limiting thereby a with level deepening and no effective months.
look data I with symptomic some start will ]. the [ Let detail. at Today, more in us
completed on X FDA. We are earnings X reminder, Cohort Slide have with discussed a X delay on that into as admit a see X, our compared expectations As Cohorts enrollment and is you to agreed actively initial the recruiting trial and still our slight and now in We recruitment as design X. last there upon call.
to due of rate the period. a mainly during higher screening is out patient drop This
level, see now and a and improvement sites more in active further patient at in we additional with site reduction the with to protocol experience a rate. However, the recruitment expect dropout
the in the [ X, rate used. combination is and line which In of in terms with infusion-related that higher study, steroid [ ] of shown on routinely note use to [ we the experience Slide premedication steroids symptomic was respectively. event It LuminICE-XXX allogeneic [ previous were to as a cells, symptomic is a part NK adverse did our profile in with expecting important of premedication studies safety, some symptomic and ] symptomic of ] not with we therefore, and a slightly for compared reactions ]
grade X patients event. X developed a infusion-related X reaction/CRS Four or of
of these as in X mainly pressure. a investigator, patients manifested and CRS by high X by One blood the which decrease Grade had assessed fever a short-lasting
treatment. the standard However, readily responded care patient to of
CMV the infection relative shortly versus this [ CMV in contribution of patient, also ] to Importantly, not overall of was there the And infusion this acute diagnosed. symptoms clear. infection is acute symptomic the the after thus, event,
due to ] there [ no were of were effects icons there or symptomic of bleeding or discontinuations side graft-versus-host disease. the instances treatment no Also, AlloNK. Importantly,
cryopreserved patients X data combination antitumor are of is data activity. that X. that as shown in independent As complete the NK Slide activity REIT Six including the the thus and by to remission. fresh and Center These for Anderson allogeneic ICE co-administration precomplexing pre reported of that terms with clinical with seem directly comparable no comparable is response a NK of cells MD [ think, combination active, an fresh I a ] with X by NK NK complexed with cells symptomic is, needed of be in were indicate an cells Cancer objective patients cells that showed remarkable, to on
data that MD underscoring at were a combination demonstrate X of and shows reproducible of therapy. from patient's patients multicenter patients these by Slide therapy had X previous with characteristics patients chemotherapy, results these single setting the site in X brentuximab. the heavily failed X study Anderson median PD-X enrolled a different as are these that Also, institutions. are pretreated, lines targeting All
of also autologous X had patients cell transplant. addition, failed stem In after X
nodes. On failed care all symptoms, unfavorable in supraclavicular inguinal presented nodes, factor. B options, with stem axillary Slide cell patient standard see patient Hodgkin's a lymphoma transplant you very prognostic his lymph of The including refractory had example clinically of is a X, lymph spleen an and lymph of multiple manifestations which with and nodes,
As resolved you only tumor of cycle one manifestations see, all after therapy. can
our Let's detail will here. move on to presentation, be data the Since brief during ASCO AFMXX. I in we presented
treatment. the documented PD-X XX, note, of cancer. chemotherapy Slide progressive there anti-PD-X atezolizumab has on EGFR responses meaningful with shown combination failed were responders non-small patients were all evaluable As X therapy. cell with combination In on and and objective patients, lung activity targeting All patients in pretreated XX and previous AFMXX disease.
Of stable had patients wild-type heavily X
months, for and responses durable can is in which than to chemotherapy, at you shown these is and appear with the these X patients treatment. long-term short. whole by data which than the to responses XX, X.X ongoing encouraging as data fact atezolizumab has compares where still months, more Slide the though than appears induced on progression-free the standard that are It explained that intervening respectively. AFMXX in be the PFS study be the these to of more now follow-up patients Importantly, X.X X of X, activity more by population usually very is the been Even tumor X favorable after very survival there see atezolizumab more control data.
The care remissions alone. achieved X months, rechallenge are occasional PD-X Even unlikely
in Even patients has only months. a survival no interval non-small lung in PD-X of atezolizumab X.X progression-free platinum shown cancer cell refractory pretreated
to non-small objective in will include difficult X cancer need cell ASCO, for achieved.
Compared the roughly salvage activity annually unsatisfactory X therapy The are PD-X patients confirmed responses wild-type standard treatment XX,XXX tolerability months. responses patients. AFMXX are of patients and is chemotherapy In are results these data EGFR-mutant have shown as for around supports general, with response EGFR treatment pretreated for combination cancer chemotherapy-free are pretreated mutant there remarkable options.
Current non-small non-small combination. care and to the disease reported market heavily that to and with of tolerate X.X markets, all shows regarded targeting In alternative as these been unresponsive a patients. who all were cell by ongoing. cell cell with on these EGFR patients lung XX fail patients the major with meanwhile, patients could atezolizumab with Also, immunotherapy.
Slide XX, durations drugs lung with plus the in that non-small is, follow-up many and lung that of recent EGFR scans cancer. non-small that AFMXX X options activity lung and the responses cancer, X Our meaningful This provide additional significantly often better heavily for stable we PFS Slide is regimens XXX,XXX as at evaluable, to cancer lung mutant opportunity refractory patients are cell XX
of most recent the review AFMXX. let's Finally, data
acute myeloid shown Our leukemia, CDXXX the targeting of on as ICE treatment XX. for Slide
escalated we Here, weekly. XXX X cohorts to through dose the have up milligrams
ability this study studies. to example a execute is the good of also of clinical I organization think our
over was The executed on XXXX is patient treated first was and in in shown The this Slide trial XX cohorts dose March in X the safety whole profile only escalation program XX. months.
manifestations patients. were X of of frequent not infusion-related or were One were X X infusion-related in responding patients short there symptomatic and mainly CRS dose-limiting a grade X Grade of no and grade self-limiting of patient Infections X, did side X. limiting characteristic all effects any half cases a leukemia toxicities. to and had treatment, The For experienced dose see most reaction, seen short-lasting IRRs. grade.
Only the reactions, we low are levels in acute higher
investigators. the treatment infections related by the However, of was none considered
responses. remission stable clinical In X X X than were we XX. remain levels nearly occupation sites note, their activation.
The pretreated. CRI, disease. meaningful tumors displayed saw of is interaction milligrams X, dose potent In the on at X complete observed Of saw and Slide and In and level X option target patients CDXX stable result complete in above, saturation after patients the to more we with XXX of with the into addition, one cells on in activities dose we NK complete X, experiments thus, on patients on CDXXX patients heavily treatment NK-cell preclinical ongoing response response of lead doses cycles level that binding and level disease, with with still respectively, with months. patients dose the All from X additional deepen a
I think are results CT's remarkable.
patients these low treatment. have start of NK with own when very of numbers cells Most advanced AML
activities support So be [ NK lymphoma NK Hodgkin that intent allogeneic and by symptomic of cells we it appears that These further in AML pursue to ] AFMXX a combination directed allogeneic products. have taken cryopreserved very with cell association of with already produce responses. cell-mediated to killing with seen low our AFMXX a leukemia to a if in strategic impressive development cells NK NK together cells numbers can complete when of data the endogenous could sensitive
treatment has based important not in system for please? The so markets, use patients Michael frequent innate again therapy this, Michael, patients elderly the been strategy chemotherapy. unmet successful treatment and of XX,XXX data. of a this, Wolf Many we of of at overview the patients.
With major therefore and AML. option. our year over we X Immunotherapy lines area require With an medical address show of our X will could additional be are close and financial and I review see over treatment clinical thus programs new of standard significant the activation these approach comorbidities, In aggressive hand the a the per of need. to who these far would failed immune on an limiting least for of the
